BioPharmSignal logoBioPharmSignal

Biotech News

IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026

Imunon (IMNN)ImunonEarnings

IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m. EST on Thursday, November 12, 2026 to discuss financial results for the quarter ended September 30, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing Phase 3 clinical development of IMNN-001 in newly diagnosed advanced ovarian cancer.

Related news

SNDXSyndax Pharmaceuticals2026-10-26 11:00 EST

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

SIGASIGA Technologies Inc2026-10-29 11:30 EST

SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

KURAKura Oncology2026-11-03 11:58 EST

Kura Oncology to Report Third Quarter Financial Results on November 10

CHRSCoherus BioSciences, Inc.2026-10-26 13:30 EST

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

GERNGeron2026-10-21 12:00 EST

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

EXELExelixis2026-10-15 20:05 EST

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

IMCRImmunocore Holdings plc2026-11-06 14:00 EST

Immunocore reports third quarter financial results and provides a business update

View all latest news

Imunon

DNA-Mediated Immunotherapy Company IMUNON develops localized gene-based immunotherapies for cancer. IMNN-001 IMNN-001 is a DNA plasmid encoding interleukin-12 delivered into the peritoneal cavity to stimulate antitumor immunity in advanced ovarian cancer. OVATION Program The Phase 3 OVATION 3 study adds IMNN-001 to frontline chemotherapy...

Recent company news

IMNNImunon2026-11-02 13:30 EST

IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026

IMNNImunon2026-10-08 13:00 EST

IMUNON to Participate in Upcoming Investor Conferences

IMNNImunon2026-09-29 12:00 EST

IMUNON Converts $1.2 Million of Debt-to-Equity

IMNNImunon2026-09-24 12:05 EST

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

IMNNImunon2026-09-22 12:05 EST

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

Stock data

Close
0.90 USD
Market cap
8.99M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States